Ritu Lal

1.1k total citations
19 papers, 429 citations indexed

About

Ritu Lal is a scholar working on Neurology, Pediatrics, Perinatology and Child Health and Epidemiology. According to data from OpenAlex, Ritu Lal has authored 19 papers receiving a total of 429 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Neurology, 5 papers in Pediatrics, Perinatology and Child Health and 5 papers in Epidemiology. Recurrent topics in Ritu Lal's work include Pharmacological Effects and Toxicity Studies (5 papers), Parkinson's Disease Mechanisms and Treatments (4 papers) and Restless Legs Syndrome Research (4 papers). Ritu Lal is often cited by papers focused on Pharmacological Effects and Toxicity Studies (5 papers), Parkinson's Disease Mechanisms and Treatments (4 papers) and Restless Legs Syndrome Research (4 papers). Ritu Lal collaborates with scholars based in United States, India and United Kingdom. Ritu Lal's co-authors include Wendy Luo, Kenneth C. Cundy, Theodora Cohen, Sandeep Dutta, Michael D. Karol, Thomas J. Ebert, Juthamas Sukbuntherng, Robin L. Blumenthal, Aaron Ellenbogen and Katie Zomorodi and has published in prestigious journals such as The American Journal of Gastroenterology, Journal of Pharmaceutical Sciences and British Journal of Clinical Pharmacology.

In The Last Decade

Ritu Lal

19 papers receiving 412 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ritu Lal United States 12 116 97 92 90 79 19 429
Paula Burger United States 6 78 0.7× 104 1.1× 30 0.3× 100 1.1× 38 0.5× 9 564
Ilona Steigerwald Germany 13 199 1.7× 190 2.0× 41 0.4× 123 1.4× 81 1.0× 20 728
S. Sjövall Finland 15 43 0.4× 266 2.7× 9 0.1× 245 2.7× 28 0.4× 23 512
Nancy Janiczek United States 4 69 0.6× 102 1.1× 29 0.3× 97 1.1× 31 0.4× 7 493
Robert Cohen United States 13 19 0.2× 73 0.8× 27 0.3× 101 1.1× 21 0.3× 31 634
William A. Speir United States 15 36 0.3× 19 0.2× 53 0.6× 60 0.7× 28 0.4× 35 542
Matthias Müller Germany 10 36 0.3× 79 0.8× 21 0.2× 52 0.6× 44 0.6× 18 396
R. Dennhardt Germany 13 23 0.2× 61 0.6× 27 0.3× 206 2.3× 8 0.1× 56 571
Bernd Lange Germany 13 98 0.8× 430 4.4× 4 0.0× 180 2.0× 158 2.0× 33 1.1k
Gagan Mahajan United States 9 18 0.2× 146 1.5× 18 0.2× 55 0.6× 18 0.2× 13 340

Countries citing papers authored by Ritu Lal

Since Specialization
Citations

This map shows the geographic impact of Ritu Lal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ritu Lal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ritu Lal more than expected).

Fields of papers citing papers by Ritu Lal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ritu Lal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ritu Lal. The network helps show where Ritu Lal may publish in the future.

Co-authorship network of co-authors of Ritu Lal

This figure shows the co-authorship network connecting the top 25 collaborators of Ritu Lal. A scholar is included among the top collaborators of Ritu Lal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ritu Lal. Ritu Lal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Yee, Shiyin, et al.. (2022). The pharmacokinetics and pharmacodynamics of dexamethasone following epidural SP-102 or intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radicular pain. International Journal of Clinical Pharmacology and Therapeutics. 60(9). 408–416. 1 indexed citations
2.
Lal, Ritu, Aaron Ellenbogen, & Barry E. Gidal. (2021). Interindividual Variability in the Bioavailability of Gabapentin Enacarbil Extended Release in Healthy Adults: An Analysis of Data From 6 Phase I Studies. Therapeutic Drug Monitoring. 44(3). 448–454. 3 indexed citations
3.
Swearingen, Dennis, et al.. (2018). Pharmacokinetics of immediate release, extended release, and gastric retentive gabapentin formulations in healthy adults. International Journal of Clinical Pharmacology and Therapeutics. 56(5). 231–238. 11 indexed citations
4.
Lal, Ritu, et al.. (2015). Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: A comparison with intravenous methylprednisolone. The Journal of Clinical Pharmacology. 56(2). 195–202. 18 indexed citations
5.
Lal, Ritu, et al.. (2012). Population Pharmacokinetics and Pharmacodynamics of Gabapentin After Administration of Gabapentin Enacarbil. The Journal of Clinical Pharmacology. 53(1). 29–40. 26 indexed citations
7.
Lal, Ritu, Aaron Ellenbogen, Dan Chen, et al.. (2012). A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study to Assess the Pharmacokinetics, Efficacy, and Safety of Gabapentin Enacarbil in Subjects With Restless Legs Syndrome. Clinical Neuropharmacology. 35(4). 165–173. 37 indexed citations
8.
LeWitt, Peter A., Aaron Ellenbogen, Dan Chen, et al.. (2012). Actively Transported Levodopa Prodrug XP21279. Clinical Neuropharmacology. 35(3). 103–110. 28 indexed citations
10.
Lal, Ritu, et al.. (2010). Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. British Journal of Clinical Pharmacology. 69(5). 498–507. 38 indexed citations
11.
Gerson, Lauren B., Amine Hila, William K. Hirota, et al.. (2009). Arbaclofen Placarbil Decreases Postprandial Reflux in Patients With Gastroesophageal Reflux Disease. The American Journal of Gastroenterology. 105(6). 1266–1275. 58 indexed citations
13.
Huff, F. Jacob, Ritu Lal, Juthamas Sukbuntherng, et al.. (2008). Clinical Evaluation of Xp19986 as a Potential Treatment for GERD. The American Journal of Gastroenterology. 103. S11–S11. 3 indexed citations
14.
Castell, Donald O., William K. Hirota, Lauren B. Gerson, et al.. (2006). XP19986 Decreases Reflux and Is Well Tolerated in GERD Patients. The American Journal of Gastroenterology. 101. S59–S59. 3 indexed citations
15.
Huang, Yue, Susanne Ostrowitzki, George Hill, et al.. (2005). Single‐ and Multiple‐Dose Pharmacokinetics of Levovirin Valinate Hydrochloride (R1518) in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(5). 578–596. 12 indexed citations
16.
Dutta, Sandeep, Ritu Lal, Michael D. Karol, Theodora Cohen, & Thomas J. Ebert. (2000). Influence of Cardiac Output on Dexmedetomidine Pharmacokinetics. Journal of Pharmaceutical Sciences. 89(4). 519–527. 103 indexed citations
17.
Lal, Ritu. (1991). Plasma protein binding and blood to plasma partitioning studies of methamphetamine. UA Campus Repository (The University of Arizona). 1 indexed citations
18.
Garg, S K, et al.. (1988). Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients.. PubMed. 26(11). 552–4. 4 indexed citations
19.
Garg, S K, et al.. (1988). Pharmacokinetics of aspirin and chloramphenicol in normal and leprotic patients before and after dapsone therapy.. PubMed. 26(4). 204–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026